Recent major research advancements have significantly expanded our understanding of psoriasis' pathophysiology, resulting in the development of highly-effective, targeted therapies. Guselkumab is the first interleukin (IL)-23-inhibitor approved for the treatment of moderate-to-severe-psoriasis, providing a new therapeutical option for psoriasis. The aim of our study was to evaluate the efficacy of guselkumab in psoriatic patients who previously failed anti-IL-12/23 and/or anti-IL-17.
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study / Ruggiero, Angelo; Fabbrocini, Gabriella; Cinelli, Eleonora; Megna, Matteo. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 34:1(2021), p. e14673. [10.1111/dth.14673]
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study
Ruggiero, Angelo;Fabbrocini, Gabriella;Cinelli, Eleonora;Megna, Matteo
2021
Abstract
Recent major research advancements have significantly expanded our understanding of psoriasis' pathophysiology, resulting in the development of highly-effective, targeted therapies. Guselkumab is the first interleukin (IL)-23-inhibitor approved for the treatment of moderate-to-severe-psoriasis, providing a new therapeutical option for psoriasis. The aim of our study was to evaluate the efficacy of guselkumab in psoriatic patients who previously failed anti-IL-12/23 and/or anti-IL-17.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
